TOP TEN perturbations for 39149_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39149_at
Selected probe(set): 208938_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39149_at (208938_at) across 6674 perturbations tested by GENEVESTIGATOR:
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-3.5518084Number of Samples:3 / 3
Experimental | echinomycin study 1 |
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
Control | deferoxamine study 5 |
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-3.151991Number of Samples:2 / 4
Experimental | R547 study 1 (24h) |
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
Control | vehicle (DMSO) treated DU145 cell sample |
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours. |
glioma study 16 (BS-149) / normal astrocyte sample
Relative Expression (log2-ratio):2.8355408Number of Samples:2 / 3
Experimental | glioma study 16 (BS-149) |
Human glioma cell line BS149 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
glioma study 16 (LN-215) / normal astrocyte sample
Relative Expression (log2-ratio):2.6594973Number of Samples:2 / 3
Experimental | glioma study 16 (LN-215) |
Human glioma cell line LN215 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
prostate cancer study 8 (ptasc) / prostate cancer study 8 (psfmc)
Relative Expression (log2-ratio):2.6309986Number of Samples:2 / 5
Experimental | prostate cancer study 8 (ptasc) |
CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy. | |
Control | prostate cancer study 8 (psfmc) |
CD49a+ FACS sorted prostate stromal fibromuscular cell (psfmc) samples from patients with primary prostate cancer collected after radical prostatectomy. |
glioma study 16 (LN-229) / normal astrocyte sample
Relative Expression (log2-ratio):2.5942106Number of Samples:2 / 3
Experimental | glioma study 16 (LN-229) |
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
R547 study 1 (6h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-2.4583807Number of Samples:4 / 4
Experimental | R547 study 1 (6h) |
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
Control | vehicle (DMSO) treated DU145 cell sample |
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours. |
glioma study 16 (LN-319) / normal astrocyte sample
Relative Expression (log2-ratio):2.1927824Number of Samples:2 / 3
Experimental | glioma study 16 (LN-319) |
Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
expO ovary cancer study 1 (dysgerminoma; metastatic) / expO ovary cancer study 1 (carcinoma, NOS; metastatic)
Relative Expression (log2-ratio):-2.1566677Number of Samples:2 / 5
Experimental | expO ovary cancer study 1 (dysgerminoma; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. | |
Control | expO ovary cancer study 1 (carcinoma, NOS; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary carcinoma (NOS) of the ovary. |
atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)
Relative Expression (log2-ratio):2.1263237Number of Samples:20 / 19
Experimental | atopic dermatitis study 12 (non-lesional; adults) |
Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
Control | atopic dermatitis study 12 (non-lesional; children) |
Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |